Type I interferons (IFNs) critically influence cancer development, progression and therapeutic response. In this Review, Parker, Haynes and colleagues explore the complexity of IFN signalling, with a particular focus on tumour-intrinsic mechanisms, and outline strategies for reprogramming IFN activity in tumours to enhance anticancer immunity and improve patient outcomes.
- Thomas B. Chadwick
- Joan So
- Belinda S. Parker